David Meek hands in his CEO title at Ipsen, leaping across the Atlantic to run a startup prepping its first US drug launch
In November Ferring spun out its late-stage bladder cancer gene therapy into a new US-based company backed by $570 million. A few weeks later the newly launched FerGene posted impressive pivotal data for the novel therapy, already under priority review at the FDA. And now the biotech will start 2020 with a high-profile CEO at the top to begin the mission on commercialization work — assuming the OK comes through.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.